Alliancebernstein L.P. Sells 151,818 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Alliancebernstein L.P. lessened its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 12.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,056,520 shares of the biopharmaceutical company’s stock after selling 151,818 shares during the period. Alliancebernstein L.P.’s holdings in Intra-Cellular Therapies were worth $88,241,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. GAMMA Investing LLC boosted its position in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of Intra-Cellular Therapies in the 4th quarter worth approximately $96,000. Wilmington Savings Fund Society FSB bought a new stake in Intra-Cellular Therapies during the 3rd quarter worth approximately $97,000. Quarry LP increased its holdings in Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Barlow Wealth Partners Inc. bought a new position in Intra-Cellular Therapies in the 4th quarter valued at $184,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock opened at $131.87 on Friday. The stock has a 50-day moving average of $129.53 and a 200-day moving average of $101.03. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.98. The stock has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ITCI shares. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Mizuho downgraded shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. StockNews.com began coverage on shares of Intra-Cellular Therapies in a report on Friday, March 28th. They issued a “hold” rating for the company. Finally, Canaccord Genuity Group downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price objective for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Eleven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $106.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.